Athira Pharma, Inc. (NASDAQ:LONA) Sees Significant Increase in Short Interest

Athira Pharma, Inc. (NASDAQ:LONA) was the target of a large growth in short interest during the month of October. As of October 15th, there was short interest totaling 87,344 shares, a growth of 355.7% from the September 30th total of 19,166 shares. Currently, 1.3% of the shares of the company are sold short. Based on an average trading volume of 726,433 shares, the short-interest ratio is currently 0.1 days.

Athira Pharma Trading Up 2.7%

Shares of LONA opened at $4.89 on Wednesday. Athira Pharma has a 12 month low of $2.21 and a 12 month high of $14.21. The stock’s 50 day moving average is $6.23 and its two-hundred day moving average is $7.59. The firm has a market cap of $45.94 million, a P/E ratio of -1.16 and a beta of 2.11.

Athira Pharma (NASDAQ:LONA) last posted its quarterly earnings data on Friday, August 14th. The company reported ($0.80) EPS for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.20). Equities research analysts forecast that Athira Pharma will post -2.67 EPS for the current year.

Analysts Set New Price Targets

Several equities research analysts have commented on the company. Mizuho lowered their price objective on Athira Pharma from $16.00 to $15.00 and set an “outperform” rating on the stock in a research report on Wednesday, August 19th. Wall Street Zen raised shares of Athira Pharma to a “hold” rating in a report on Saturday, October 17th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Athira Pharma in a report on Friday, August 7th. Finally, Citizens Jmp lowered their price target on shares of Athira Pharma from $18.00 to $17.00 and set a “market outperform” rating on the stock in a report on Monday, August 17th. Four equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Athira Pharma presently has a consensus rating of “Moderate Buy” and a consensus price target of $17.33.

Athira Pharma Company Profile

Athira Pharma is a clinical-stage biotechnology company focused on developing regenerative therapies for neurodegenerative diseases. Its research has centered on treatments intended to activate the hepatocyte growth factor pathway, which may support neuronal health, repair, and regeneration.

The company’s lead investigational product is fosgonimeton, formerly known as ATH-1017, an intravenous therapy developed for potential use in Alzheimer’s disease and other neurodegenerative conditions.